Corporate Strategy, Business Development
Bob Smith is an accomplished biopharmaceutical executive with over 35 years’ experience in a variety of alliance management, business development, commercial, corporate, mergers and acquisitions, and research and development roles. From 2016 to 2024 when he retired from Pfizer, Bob was responsible for leading Pfizer’s Global Gene Therapy Business including the strategic and operational development and implementation of Pfizer’s end-to-end, enterprise-wide efforts to be an industry leader in gene therapy.
Expertise
- The business of rare disease research and commercial development
- Global mergers and acquisitions in healthcare and biotech
Experience
- Former global gene therapy business lead for Pfizer
- Leading worldwide business development for Pfizer’s Worldwide Research and Development organization and its Strategic Transitions team
- Serving/served on boards of directors for M Pharma B.V., Bamboo Therapeutics Inc., Citius Pharmaceuticals, Inc., CureDuchenne, Ignite Immunotherapeutics Inc., Iterum Therapeutics Limited, Life Sciences PA – the Pennsylvania Biotechnology Association, Bio NJ – the New Jersey State Biotechnology Association, the Duke Margolis Value Based Agreements Advisory Board, the Alliance for Regenerative Medicine (ARM) and the Foundation for Cell and Gene Medicine (FCGM)